MedDay Pharmaceuticals is developing high-dose pharmaceutical biotin for treatment of progressive forms of MS. Currently in phase III development, there is an ongoing clinical trial in Europe and the US named SPI2.
Some articles I’ve read argue that this treatment can stop progression and has induced a mild reversion of disability in a few patients. Given that biotin has no anti inflammatory effect, is this an add on treatment to DMTs approved or used in PPMS? (ocrelizumab, rituximab, etc)
Can we expect to have more info on this treatment after ECTRIMS 2018 this coming October?
Opinions? More Information?
Browse categories and add by clicking on them
You can remove current categories below by clicking the ‘x’.